SLO ENG
INERHC (Institute of Economic Research in Health Care)



INERHC EXPERT REFERENCES

Below you will find only the references which are not subject to confidentiality:

 


 

Cost-effectiveness analysis of Natalizumab for multiple sclerosis treatment in Slovenia

April 2010


Mrkaić M., Živkovič A., " Cost-Effectiveness Analysis of Natalizumab for Multiple Sclerosis Treatment in Slovenia", April 2010

 

 


Budget impact analysis of introduction of Natalizumab for multiple sclerosis treatment in Slovenia

April 2010


Mrkaić M., Živkovič A., " Budget impact analysis of introduction of Natalizumab for multiple sclerosis treatment in Slovenia ", April 2010



 

Additional health insurance from tax perspective: Effects of additional health insurance on public finance and national economy in Slovenia

October 2009

 



Analysis of economic effects of palivizumab usage in Slovenian setting: Cost-effectiveness of palivizumab in the cases of heavier respiratory infections with respiratory syncytial virus for high-risk children

June 2009

 

Mrkaić M., Živkovič A., "Analysis of economic effects of palivizumab consumption in Slovenian setting: Cost-effectiveness of palivizumab in the cases of heavier respiratory infections with respiratory syncytial virus for high-risk children", June 2009

 

 

 

Effects of potential transfer of additional health insurance into compulsory health insurance from the national economy and public finance perspectives

September 2008

 

Mrkaić M., Pezdir R., Živkovič A., "Effects of potential transfer of additional health insurance into compulsory health insurance from the national economy and public finance perspectives", September 2008

 

 

 

Economic analysis of the Slovenian pharmacy financing system

July 2008

 

Mrkaić M., Živkovič A., Pezdir R., "Economic analysis of the pharmacy financing system", July 2008

 

 

  

INERHC annual economic research of the Slovenian health care system

June 2008

 

Živkovič A., Mrkaić M., Pezdir R., Hočevar F., Eržen I., Albreht T.: Zdravstvena ekonomika – revija za ekonomske raziskave v zdravstvu, June 2008

 

 

 

Health Technology Assessment (HTA) guidelines, 1st Edition

January 2008

 

Živkovič A., Pezdir R., Mrkaić M.: Health Technology Assessment (HTA) guidelines, 1st Edition, January 2008

 


 

Differential cost-effectiveness of natalizumab compared to interferon beta-1a: Analysis for Slovenia

January 2008

 

Mrkaić M., Pezdir R., "Differential cost-effectiveness of natalizumab compared to interferon beta-1a: Analysis for Slovenia", January 2008

 

 


Economic analysis of cost-effectiveness of natalizumab in multiple sclerosis treatment

December 2007

 

Mrkaić M., Pezdir R., "Economic analysis of cost-effectiveness of natalizumab in multiple sclerosis treatment", December 2007

 

 The article is available here.


 

 

Drug spend cost containment measures of pricing and reimbursement policies from the perspective of economic efficiency

November 2007


Živkovič A., " Drug spend cost containment measures of pricing and reimbursement policies from the perspective of economic efficiency", Bilten: ekonomika, organizacija, informatika v zdravstvu, december 2007, letnik 23, številka 4 (IVZ)

 

http://www.ivz.si/javne_datoteke/bilten/datoteke/85-Zivkovic.pdf

 


 

Restrictions of hospital operation: roots of inefficiency of Slovenian health care

November 2007

 

Pezdir R, Mrkaić M., "Restrictions of hospital operation: roots of inefficiency of Slovenian health care", Bilten: ekonomika, organizacija, informatika v zdravstvu, december 2007, letnik 23, številka 4 (IVZ)

 

http://www.ivz.si/javne_datoteke/bilten/datoteke/83-Mrkaic.pdf

 


 

Analysis of economic efficiency of public spend allocation in health care

November 2007

 

Addressee:

  • Ministry of Health of the Republic of Slovenia

 

Expert and financially independent research, which has been prepared based on initiation from the Ministry of Health of the Republic of Slovenia. The research is coping with quantification of inefficiency of the health care spend allocation.

 

 

 

Quantification of economic factors of TYSABRI (natalizumab)

November 2007

 

 

 

Quantification of economic factors of BYETTA (exenatide)

November 2007

 

 

 

Quantification of economic factors of JANUVIA (sitaglipin)

November 2007

 

 

 

Quantification of economic factors of ARCOXIA (etoricoxib)

November 2007

 

 

 

Optimization of salary system in healthcare

November 2007

 

Addressees:

  • Ministry of Health of the Republic of Slovenia
  • The Health Insurance Institute of Slovenia (ZZZS)

 

The document has been prepared based on initiation and wish of The Health Insurance Institute of Slovenia (ZZZS) and consists of a short description of the salary system issues in Slovenian healthcare. The document also proposes some of potential solutions for optimization of the issue.

 

 

 

Optimization of cost-efficiency of drug spend

November 2007

 

Addressee:

  • The Health Insurance Institute of Slovenia (ZZZS)

 

The document has been prepared based on initiation from The Health Insurance Institute of Slovenia (ZZZS) and consists of description of current health-economic problematic issues (with potential solutions) in the areas of (1) analytics of drug spend and prescription patterns with the purpose of searching for post-marketing clinical studies, (2) analytics of drug spend and prescription patterns with the purpose of rational prescription stimulation model for contractual parties of The Health Insurance Institute of Slovenia (ZZZS).

 

 

 

Regulatory changes in some areas of allocation and regulation of public drug spend

October 2007

 

Addressee:

  • Ministry of Health of the Republic of Slovenia

 

The document has been prepared based on initiation and wish of the Ministry of Health of the Republic of Slovenia and consists of economic basis and recommendations for potential changes of the following systems: (1) Drug reimbursement system and other systems of public drug spend allocation, (2) Drug pricing regulation, (3) The issues of the current system of post-marketing clinical studies from the perspective of economic efficiency of public drug spend allocation and from the perspective of the effect of post-marketing clinical studies on labor cost and productivity of healthcare professionals.

 

 

 

Evaluation of cost-effectiveness of PROTELOS (strontium ranelate)

August 2007
 

 


INERHC economic research: "Is the Slovenian health care system facing a breakdown?"

May 2007

 

Independent expert research which is, from the perspective of optimization of economic efficiency, trying to cope with areas such as efficient drug spend allocation and drug pricing regulation, issues of management and organization in healthcare, productivity and other problematic areas of health care.

 

Živkovič A., Pezdir R, Mrkaić M., Hočevar F. "Is the Slovenian health care system facing a breakdown?". Zdravstvena ekonomika – revija za ekonomske raziskave v zdravstvu, May 2007